Treatment adverse events summary
| All patients | Sofosbuvir+ ledipasvir | Glecaprevir+ pibrentasvir | Sofosbuvir +velpatasvir | |||||
| Number | % | Number | % | Number | % | Number | % | |
| Adverse events | 47 | 10.00 | 17 | 34.00 | 26 | 7.54 | 4 | 5.33 |
| Pruritus: grade 1 | 22 | 4.68 | 4 | 8.00 | 17 | 4.93 | 1 | 1.33 |
| Pruritus: grade 2 | 3 | 0.64 | 0 | 0.00 | 3 | 0.87 | 0 | 0.00 |
| Nausea/vomit | 1 | 0.21 | 0 | 0.00 | 1 | 0.29 | 0 | 0.00 |
| Diarrhoea | 4 | 0.85 | 3 | 6.00 | 1 | 0.29 | 0 | 0.00 |
| Anorexia | 4 | 0.85 | 0 | 0.00 | 4 | 1.16 | 0 | 0.00 |
| Thrombocytopenia | 1 | 0.21 | 1 | 2.00 | 0 | 0.00 | 0 | 0.00 |
| Headache | 8 | 1.70 | 6 | 12.00 | 2 | 0.58 | 0 | 0.00 |
| Dizziness | 6 | 1.28 | 1 | 2.00 | 3 | 0.87 | 2 | 2.67 |
| Fatigue | 8 | 1.70 | 3 | 6.00 | 5 | 1.45 | 0 | 0.00 |
| Fever | 1 | 0.21 | 1 | 2.00 | 0 | 0.00 | 0 | 0.00 |
| Liver function impairment | ||||||||
| ALT>ULN ~3×ULN | 18 | 3.83 | 4 | 8.00 | 10 | 2.90 | 4 | 5.33 |
| Total bilirubin >ULN ~1.5×ULN | 34 | 7.23 | 4 | 8.00 | 27 | 7.83 | 3 | 4.00 |
| >1.5 ~3×ULN | 9 | 1.91 | 2 | 4.00 | 6 | 1.74 | 1 | 1.33 |
| HBV reactivation | 4 | 9.09 | 0 | 0.00 | 3 | 8.82 | 1 | 14.29 |
ALT, alanine transaminase; HBV, hepatitis B virus; ULN, upper limited normal.